• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS Achieves Important Milestones in Partnership with Roche

Leiden, March 3, 2023 – MIMETAS has achieved major milestones in its partnership with Roche, developing models for Inflammatory Bowel Disease (IBD) and Hepatitis B Virus infections (HBV).

In July 2021, MIMETAS and Roche entered a risk-sharing collaboration to develop human disease models for the characterization of novel compounds in Inflammatory Bowel Disease (IBD) and Hepatitis B virus infections (HBV). You can find the original press release here.

"We have achieved critical milestones in modeling the human gut, IBD, and HBV infection in the laboratory,” says Jos Joore, CEO of MIMETAS. “This success required hard work, tenacity, and technological and biological know-how. I’m proud of our scientific team that made this possible and grateful for Roche’s trust in our capabilities. We will keep pushing the boundaries of human disease models to lead the way in deploying these for first-in-class target and compound discovery."

IBD is a chronic inflammatory disorder affecting multiple gastrointestinal tract segments. Its multifactorial nature renders the condition challenging to diagnose and treat. The current treatment options for IBD, which include corticosteroids and anti-TNF biologics, are associated with significant side effects and do not work for a large group of patients. Similarly, HBV is a complex viral infection that can cause liver damage and increase the risk of liver cancer. Existing HBV treatments are limited in their efficacy, and developing novel therapeutics has been challenging due to the rapid mutation of the virus. The development of effective, novel therapies for IBD and HBV has been challenging due to the complexity of these diseases and the limited availability of physiologically-relevant human models for drug discovery.


Sign up for our Newsletter

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all